

Ministry of Health

Health Programs and Delivery Division

Drug Submission Status

Report for August 2025

Complete Streamlined Multiple-Source Submissions for Future Formulary Listing

The Ministry of Health has received complete submissions for the following streamlined multiple-source drug products for listing on the Ontario Drug Benefit Formulary. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be listed as benefits in a future Formulary update. Final listing status will be communicated when the Formulary update is published on the Ministry website and via an HPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Apotex Inc.	Apo-Sitagliptin	Januvia	SITAGLIPTIN	25 mg	tablet	02428261
Apotex Inc.	Apo-Sitagliptin	Januvia	SITAGLIPTIN	50 mg	tablet	02428288
Apotex Inc.	Apo-Sitagliptin	Januvia	SITAGLIPTIN	100 mg	tablet	02428296
Jamp Pharma Corporation	Jamp Lisdexamfetamine	Vyvanse	LISDEXAMFETAMINE DIMESYLATE	10 mg	capsule	02535122
Jamp Pharma Corporation	Jamp Lisdexamfetamine	Vyvanse	LISDEXAMFETAMINE DIMESYLATE	20 mg	capsule	02535130
Jamp Pharma Corporation	Jamp Lisdexamfetamine	Vyvanse	LISDEXAMFETAMINE DIMESYLATE	30 mg	capsule	02535149
Jamp Pharma Corporation	Jamp Lisdexamfetamine	Vyvanse	LISDEXAMFETAMINE DIMESYLATE	40 mg	capsule	02535157
Jamp Pharma Corporation	Jamp Lisdexamfetamine	Vyvanse	LISDEXAMFETAMINE DIMESYLATE	50 mg	capsule	02535165

Jamp Pharma Corporation	Jamp Lisdexamfetamine	Vyvanse	LISDEXAMFETAMINE DIMESYLATE	60 mg	capsule	02535173
Marcan Pharmaceuticals Inc.	Mar-Doxepin	Sinequan	DOXEPIN HYDROCHLORIDE	10 mg	capsule	02559080
Marcan Pharmaceuticals Inc.	Mar-Doxepin	Sinequan	DOXEPIN HYDROCHLORIDE	25 mg	capsule	02559099
Marcan Pharmaceuticals Inc.	Mar-Doxepin	Sinequan	DOXEPIN HYDROCHLORIDE	50 mg	capsule	02559102